FDA grants approval status for Hikma's Epinephrine application
The FDA has granted an approval status (AP) for Hikma's original application (ANDA220562) for Epinephrine, indicating that the product is progressing through the regulatory process.
Therapeutic Area
Therapeutic area intelligence for Anaphylaxis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.